Kathleen Garland, Eric Mullins, Rachel S Bercovitz, Vilmarie Rodriguez, Jean Connors, Nancy Sokkary
Gender dysphoria or gender incongruence is defined as "persons that are not satisfied with their designated gender" [1]. The awareness and evidence-based treatment options available to this population have grown immensely over the last two decades. Protocols now include an Endocrine Society Clinical Practice Guideline [1] as well as the World Professional Association of Transgender Health Standards of Care (WPATH SOC) [2]. Hematologic manifestations, most notably thrombosis, are one of the most recognized adverse reactions to the hormones used for gender-affirming care...
September 14, 2023: Thrombosis Research
Harsha Tathireddy, Douglas Rice, Kylee Martens, Sudeep Shivakumar, Joseph Shatzel
Tumor thrombus, the intravascular extension of tumor into adjacent blood vessels, is frequently encountered in patients with renal cell carcinoma and hepatocellular carcinoma, and often involves the abdominal vasculature including the renal vein, portal vein, and the inferior vena cava. While a bland thrombus is composed of platelets and fibrin, in contrast, a tumor thrombus refers to an organized collection of tumor cells. Though oftentimes detected incidentally on imaging, tumor thrombus may have significant clinical implications and can be challenging to differentiate from bland thrombus...
September 13, 2023: Thrombosis Research
Anna N Balandina, Ekaterina M Koltsova, Alexey M Shibeko, Anna D Kuprash, Valentina A Budkova, Irina A Demina, Anastasiya A Ignatova, Olga A Fadeeva, Ramya Vijay, Sukesh C Nair, Alok Srivastava, Qiang Shi, Fazoil I Ataullakhanov, Mikhail A Panteleev
Activated platelets provide phospholipid surface and secrete coagulation factors, enhancing blood clotting. We investigated the role of platelets in the regulation of blood coagulation spatial dynamics. We activated blood clotting with tissue factor-bearing (TF) surface in platelet-rich plasma (PRP) or platelet-free plasma (PFP). When blood coagulation was initiated by high TF density, clot growth rate (V) in PRP (2 × 105 /μL platelets) was only 15 % greater than in PFP. Spatial distribution of thrombin in PRP had a peak-like shape in the area of the fibrin clot edge, while in PFP thrombin was distributed in the shape of descending plateau...
September 13, 2023: Thrombosis Research
Rui Terada, Penny M Johnson, Amir L Butt, Yuko Mishima, Kenneth E Stewart, Jerold H Levy, Kenichi A Tanaka
BACKGROUND: Andexanet alfa is a Gla-domainless FXa (GDXa) analog used as an antidote to FXa inhibitors. Despite its clinical use, laboratory monitoring for anti-Xa reversal and the effect of andexanet on fibrinolysis has not been explored. We used a GDXa with a serine-to-alanine mutation at position 195 (chymotrypsin numbering) to model the interaction between andexanet and apixaban. METHODS: Six batches of pooled plasma, and whole blood from healthy volunteers were treated with increasing concentrations of apixaban with/without GDXa...
September 9, 2023: Thrombosis Research
G Baidildinova, A Pallares Robles, V Ten Cate, B M M Kremers, S Heitmeier, H Ten Cate, B M E Mees, H M H Spronk, P S Wild, A J Ten Cate-Hoek, K Jurk
BACKGROUND: A significant proportion of patients with peripheral artery disease (PAD) displays a poor response to aspirin and/or the platelet P2Y12 receptor antagonist clopidogrel. This phenomenon is reflected by high on-treatment platelet reactivity (HTPR) in platelet function assays in vitro and is associated with an increased risk of adverse cardiovascular events. OBJECTIVE: This study aimed to elucidate specific plasma protein signatures associated with HTPR to aspirin and clopidogrel in PAD patients...
September 2, 2023: Thrombosis Research
Gordon Chu, Jaap Seelig, Suzanne C Cannegieter, Hans Gelderblom, Marcel M C Hovens, Menno V Huisman, Tom van der Hulle, Serge A Trines, André J Vlot, Henri H Versteeg, Martin Hemels, Frederikus A Klok
BACKGROUND AND AIMS: Cancer provides challenges to the continuity of anticoagulant treatment in patients with atrial fibrillation (AF), e.g. through cancer-related surgery or complications. We aimed to provide data on the incidence and reasons for interrupting and discontinuing anticoagulant treatment in AF patients with cancer and to assess its contribution to the risk of thromboembolism (TE) and major bleeding (MB). METHODS: This retrospective study identified AF patients with cancer in two hospitals between 2012 and 2017...
August 30, 2023: Thrombosis Research
Ahmed Alarabi, Anne Hubben, John Barnard, Jason S Knight, Keith R McCrae
No abstract text is available yet for this article.
August 30, 2023: Thrombosis Research
Qi Chen, Jing Chen, Jiahua Li, Yuanyuan Cheng, Rong Zhang, Zhongqiu Liu
Oxidative stress (OS) has been identified as a key factor in the development of Thromboangiitis Obliterans (TAO). The detection of OS levels in clinical and scientific research practice is mainly based on the measurement of oxidative stress such as reactive oxygen species (ROS), reactive nitrogen species (RNS) and lipid peroxides. These markers are typically assessed through a combination of physical and chemical methods. Smoking is known to the state of OS in TAO, and OS levels are significantly increased in smokers due to inadequate antioxidant protection, which leads to the expression of apoptotic proteins and subsequent cell injury, thrombosis and limb ischemia...
August 25, 2023: Thrombosis Research
Xian Li, Xiaohong Song, Dlovan F D Mahmood, Martha M S Sim, Sara J Bidarian, Jeremy P Wood
INTRODUCTION: Thrombin, the enzyme which converts fibrinogen into a fibrin clot, is produced by the prothrombinase complex, composed of factor Xa (FXa) and factor Va (FVa). Down-regulation of this process is critical, as excess thrombin can lead to life-threatening thrombotic events. FXa and FVa are inhibited by the anticoagulants tissue factor pathway inhibitor alpha (TFPIα) and activated protein C (APC), respectively, and their common cofactor protein S (PS). However, prothrombinase is resistant to either of these inhibitory systems in isolation...
August 23, 2023: Thrombosis Research
Eduardo Fuentes, Diego Arauna, Ramiro Araya-Maturana
Platelet activation plays an essential role in the pathogenesis of thrombotic events in different diseases (e.g., cancer, type 2 diabetes, Alzheimer's, and cardiovascular diseases, and even in patients diagnosed with coronavirus disease 2019). Therefore, antiplatelet therapy is essential to reduce thrombus formation. However, the utility of current antiplatelet drugs is limited. Therefore, identifying novel antiplatelet compounds is very important in developing new drugs. In this context, the involvement of mitochondrial function as an efficient energy source required for platelet activation is currently accepted; however, its contribution as an antiplatelet target still has little been exploited...
August 22, 2023: Thrombosis Research
Stefano Barco, Saverio Virdone, Andrea Götschi, Walter Ageno, Juan I Arcelus, Roland Bingisser, Giuseppe Colucci, Frank Cools, Daniel Duerschmied, Harry Gibbs, Riccardo M Fumagalli, Bernhard Gerber, Sylvia Haas, Jelle C L Himmelreich, Richard Hobbs, Lukas Hobohm, Barry Jacobson, Gloria Kayani, Renato D Lopes, Peter MacCallum, Evy Micieli, Marc Righini, Helia Robert-Ebadi, Ana Thereza Rocha, Thomas Rosemann, Jitendra Sawhney, Sebastian Schellong, Tim Sebastian, David Spirk, Stefan Stortecky, Alexander G G Turpie, Davide Voci, Nils Kucher, Karen Pieper, Ulrike Held, Ajay K Kakkar
BACKGROUND: Antithrombotic treatment may improve the disease course in non-critically ill, symptomatic COVID-19 outpatients. METHODS: We performed an individual patient-level analysis of the OVID and ETHIC randomized controlled trials, which compared enoxaparin thromboprophylaxis for either 14 (OVID) or 21 days (ETHIC) vs. no thromboprophylaxis for outpatients with symptomatic COVID-19 and at least one additional risk factor. The primary efficacy outcome included all-cause hospitalization and all-cause death within 30 days from randomization...
August 18, 2023: Thrombosis Research
Emanuele Valeriani, Daniele Pastori, Giulia Astorri, Angelo Porfidia, Danilo Menichelli, Pasquale Pignatelli
INTRODUCTION: The role of inherited thrombophilia in arterial disease is uncertain. We performed a systematic-review and meta-analysis of inherited thrombophilia in cerebrovascular (CVD), coronary heart (CHD), and peripheral artery disease (PAD) patients. MATERIALS AND METHODS: MEDLINE and EMBASE were searched up to February 2022. Pooled prevalences (PPs) and odds ratios (ORs) with 95 % confidence intervals (95%CI) were calculated in a random-effects model...
August 16, 2023: Thrombosis Research
Yuta Imai, Satomi Nagaya, Yuhei Araiso, Makiko Meguro-Horike, Tomoki Togashi, Shin-Ichi Horike, Hiroshi Kawasaki, Eriko Morishita
INTRODUCTION: Hereditary antithrombin (AT) deficiency type I causes venous thrombosis due to decreased levels of AT antigen in the blood. We identified one novel and one known abnormal variant in two unrelated Japanese families with venous thrombosis. In this study, we analyzed the mechanism by which these abnormal variants cause type I AT deficiency. MATERIALS AND METHODS: Wild-type and variant AT expression vectors were constructed and transiently expressed in human embryonic kidney 293 cells, and AT antigen levels and N-glycosylation of cell lysates and culture medium were evaluated by western blot analysis...
August 15, 2023: Thrombosis Research
Alessandra Bettiol, Flavia Rita Argento, Eleonora Fini, Federica Bello, Gerardo Di Scala, Niccolò Taddei, Giacomo Emmi, Domenico Prisco, Matteo Becatti, Claudia Fiorillo
BACKGROUND: Cranial and extra-cranial vascular events are among the major determinants of morbidity and mortality in Giant Cell Arteritis (GCA). Vascular events seem mostly of inflammatory nature, although the precise pathogenetic mechanisms are still unclear. We investigated the role of oxidation-induced structural and functional fibrinogen modifications in GCA. The effects of the anti-IL6R tocilizumab in counteracting these mechanisms were also assessed. MATERIALS AND METHODS: A cross-sectional study was conducted on 65 GCA patients and 65 matched controls...
August 15, 2023: Thrombosis Research
Marion Bareille, Thomas Lecompte, François Mullier
No abstract text is available yet for this article.
August 13, 2023: Thrombosis Research
Rahel Villiger, Pauline Juillard, Pauline Darbellay Farhoumand, Damien Choffat, Tobias Tritschler, Odile Stalder, Jean-Benoît Rossel, Drahomir Aujesky, Marie Méan, Christine Baumgartner
INTRODUCTION: Pharmacological thromboprophylaxis slightly increases bleeding risk. The only risk assessment model to predict bleeding in medical inpatients, the IMPROVE bleeding risk score, has never been validated using prospectively collected outcome data. METHODS: We validated the IMPROVE bleeding risk score in a prospective multicenter cohort of medical inpatients. Primary outcome was in-hospital clinically relevant bleeding (CRB) within 14 days of admission, a secondary outcome was major bleeding (MB)...
August 12, 2023: Thrombosis Research
David M Scott, Abdi Abud, Mostafa Amor, Arash Saemi, Lisa Baumann Kreuziger, Damon Houghton
No abstract text is available yet for this article.
August 12, 2023: Thrombosis Research
Tobias Harm, Dominik Rath, Klaus-Peter Kreisselmeier, Livia Baas, Carolin Prang, Sarah Gekeler, Stephen Schröder, Meinrad Paul Gawaz, Tobias Geisler, Iris Irmgard Müller, Karin Anne Lydia Müller
BACKGROUND: Intracoronary thrombus formation is a main cause of acute myocardial infarction triggered by platelet activation. However, there are no data on the impact of different treatment strategies with antiplatelet agents before percutaneous coronary intervention (PCI) on histological characteristics of thrombus formation. OBJECTIVE: In this study, we investigate the impact of preinterventional administration of the P2Y12-inhibitors clopidogrel and prasugrel on thrombus composition, highlighting significant changes associated with the antiplatelet pre-treatment...
August 11, 2023: Thrombosis Research
Gonçalo Felix, Ester Ferreira, Ana Ribeiro, Inês Guerreiro, Emanuel Araújo, Sara Ferreira, Sara Coelho, Helena Magalhães, Jorge Almeida, Patrícia Lourenço
BACKGROUND: Acute pulmonary embolism (PE) can occur as a manifestation of an underlying cancer and be of paraneoplastic aetiology. A previously unknown cancer is sometimes diagnosed after the acute PE diagnosis. The identification of a group of patients with elevated probability of having an occult cancer underlying PE was never performed. We aimed to determine predictors of occult cancer in acute PE. Our hypothesis was that the D-dimer levels would be a predictor of cancer. PATIENTS AND METHODS: We retrospectively analysed a cohort of patients hospitalized with acute PE...
August 11, 2023: Thrombosis Research
Ran Mo, Hao-Yu Wang, Yan-Min Yang, Han Zhang, Ni Suo, Jing-Yang Wang
INTRODUCTION: The association between bleeding and subsequent major adverse cardiac and cerebrovascular events (MACCE) remains poorly characterized. We aimed to evaluate the impact of hemorrhagic events in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI). MATERIALS AND METHODS: A total of 1877 consecutive patients with AF and ACS or undergoing PCI were prospectively recruited. The primary endpoint was MACCE, including all-cause death, myocardial infarction, ischemic stroke, systemic embolism or ischemia-driven revascularization during follow-up...
August 6, 2023: Thrombosis Research
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.